Spatiotemporal Stereotactic Body Radiation Therapy for the Treatment of Patients With Polymetastatic Solid Tumors (NCT05733949)

🧪 Interventions in This Study

• Biospecimen Collection (PROCEDURE)
• Computed Tomography (PROCEDURE)
• Stereotactic Body Radiation Therapy (RADIATION)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Documented informed consent of the participant and/or legally authorized representative
2. Assent, when appropriate, will be obtained per institutional guidelines
3. Age: \>= 18 years
4. Karnofsky performance status \> 60
5. Poly-metastatic disease, \> 5 lesions, and with at least one lesion \> 2.0 cm, with limited treatment options, and ineligible for or in progression under the standard systemic therapy
6. Pre-screening assessment confirms that the intervention can be administered without exceeding dose constraint guidelines
7. Patients with brain metastases can be included but brain metastases must be treated prior to enrollment and follow up magnetic resonance imaging (MRI) 3 months after treatment shows stable findings
8. Spinal cord metastases are allowed as long as treatment with or without radiation is completed
9. Prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints
10. Life expectancy \>= 3 months in the opinion of the treating investigators
11. Off systemic therapy for at least one month prior and one month after study intervention

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

• City of Hope Medical Center — Duarte, California

📞 Contact the Study Coordinator

Phone: (626) 218-4589

Email: yichen@coh.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Malignant Solid Neoplasm

• Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations — Seattle, Washington
• Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes — Duarte, California
• Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial — Birmingham, Alabama
• Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR) — Duarte, California
• Improving Processes of Cancer Care Delivery at a Comprehensive Cancer Center — Houston, Texas

Explore by condition: All Metastatic Malignant Solid Neoplasm clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.